TTrialPathMatch Me to Trials
← Back to trials
RecruitingAdvanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Sponsor: Frontier Medicines Corporation

You may qualify if…

  • ✓ Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors with KRAS G12C mutation
  • ✓ Received and progressed or been intolerant to prior standard therapy OR standard therapy is considered inappropriate OR an investigational agent is considered standard of care
  • ✓ NSCLC Participants (in the first-line advanced or metastatic setting who refused standard therapy or standard therapy was considered inappropriate)
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • ✓ Adequate hematological, renal, and hepatic function
  • ✓ Agrees not to participate in another interventional study while receiving study drug
  • ✓ For patients receiving FMC-376 in combination with pembrolizumab: No history of autoimmune disease, and no history of immune-related adverse events or hepatitis

You may not qualify if…

  • ✕ Leptomeningeal disease or carcinomatous meningitis
  • ✕ Clinically significant toxicity resulting from prior cancer therapies
  • ✕ Known or suspected hypersensitivity to FMC-376 or any components of the study drug
  • ✕ Condition that would interfere with study drug absorption
  • ✕ Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
  • ✕ For patients receiving FMC-376 in combination with pembrolizumab: Has severe hypersensitivity (≥ Grade 3) to pembrolizumab, history of radiation-related toxicities, or history of non-infectious pneumonitis.

Where it's recruiting

California

La Jolla · Orange · San Francisco

Florida

Lake Mary

Kansas

Fairway

Michigan

Detroit

Pennsylvania

Philadelphia

Texas

Houston · Kingwood · San Antonio

Utah

West Valley City

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT06244771 · last updated 2026-10-19